DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Melanoma - Pipeline Review, H1 2016" report to their offering.
Melanoma - Pipeline Review, H1 2016 outlays comprehensive information on the therapeutics under development for Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in therapeutic development for Melanoma and features dormant and discontinued projects.
Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.
Melanoma pipeline therapeutics constitutes close to 516 molecules, out of which approximately 427 molecules are developed by Companies and remaining by Universities/Institutes. The molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 17, 82, 91, 2, 206, 25 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 12, 10, 54 and 12 molecules, respectively.
Key Topics Covered:
- Introduction
- Melanoma Overview
- Therapeutics Development
- Pipeline Products for Melanoma - Overview
- Pipeline Products for Melanoma - Comparative Analysis
- Melanoma - Therapeutics under Development by Companies
- Melanoma - Therapeutics under Investigation by Universities/Institutes
- Melanoma Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Melanoma - Products under Development by Companies
- Melanoma - Products under Investigation by Universities/Institutes
- Melanoma - Companies Involved in Therapeutics Development
For more information about this report visit http://www.researchandmarkets.com/research/cpjnwc/melanoma
Related Topics: Skin Cancer Drugs
